कंपनी का अवलोकन
RxSight, Inc. operates as a commercial-stage medical technology enterprise focused on the research, development, manufacturing, and distribution of light-adjustable intraocular lenses (LAL) utilized specifically within cataract surgery procedures across the United States. The company functions within the broader healthcare sector, specifically targeting the medical devices industry, which implies a reliance on regulatory approvals and specialized clinical applications for its product offerings. According to available data, the enterprise possesses a total market capitalization of $300.42M and generates annual revenue of $134.48M over the trailing twelve-month period. The organization maintains a workforce size of 461 employees, reflecting an established operational footprint within the niche medical optics market. These valuation and revenue figures indicate that the company holds a significant but volatile position in a specialized segment, where the market cap of $300.42M suggests investor interest despite the current lack of profitability, while the revenue scale demonstrates a substantial commercial presence in the intraocular lens landscape.
वित्तीय स्वास्थ्य
The company reported a revenue of $134.48M for the trailing twelve months, yet it recorded a net income of -$38,944,000 and an EBITDA of -$44,925,000, highlighting a substantial disparity between top-line generation and bottom-line profitability. This significant gap between revenue and net income reveals a cost structure characterized by high operating expenses that are not fully covered by gross profits, resulting in a net loss that impacts the overall equity value. The firm generated free cash flow of -$1,625,250, indicating a negative cash position that limits immediate financial flexibility and suggests a reliance on existing cash reserves to fund operations and development efforts. Profitability is further contextualized by a gross margin of 76.6%, which indicates strong pricing power or high-value manufacturing, contrasted sharply by an operating margin of -34.8% and a profit margin of -29.0% that demonstrate severe inefficiencies in overhead control or high research and development expenditures. The balance sheet shows a cash position of $228.13M against total debt of $11.04M, resulting in a debt-to-equity ratio of 4.00, which indicates a highly leveraged capital structure relative to equity but provides a robust liquidity buffer for debt servicing. Short-term liquidity appears robust with a current ratio of 10.95, suggesting the company holds ample current assets to cover its short-term liabilities without immediate distress. However, the return metrics tell a story of capital destruction, with a return on equity of -14.0% and a return on assets of -9.6%, revealing that management has not yet achieved positive returns on the invested capital or asset base, reflecting ongoing challenges in converting operational scale into shareholder value.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E stands at -15.09, implying that the market expects earnings to remain negative in the near term or that valuation models are relying on future cash flow projections rather than historical profitability. The price-to-book ratio is 1.09, indicating that the market values the company slightly above its net asset book value, which is typical for growth-oriented biotech or medtech firms where intangible assets and future pipeline potential are priced in despite current losses. Alternative valuation metrics such as the price-to-sales ratio of 2.23 and an EV/EBITDA of -1.85 suggest that investors are pricing the stock based on revenue multiples rather than earnings, signaling confidence in future revenue expansion rather than immediate profit generation. The stock's trading range over the last year spans a 52-week high of $17.52 and a 52-week low of $5.90, providing a clear band within which the security has fluctuated based on market sentiment regarding its clinical pipeline and regulatory milestones. The beta value of 1.21 indicates that the stock's price volatility is approximately 21% higher than the broader market, reflecting the inherent risks associated with the medical device sector, including clinical trial failures and regulatory approval delays. These valuation parameters collectively suggest that the stock is priced for significant growth potential, as evidenced by the forward P/E and P/S metrics, despite the current financial headwinds indicated by the negative EV/EBITDA.
Growth & Income
The revenue growth year-over-year is -18.9%, while earnings growth is listed as N/A due to the company's loss-making status, indicating that the company is currently shrinking in terms of top-line revenue rather than expanding. The absence of earnings growth combined with negative revenue growth implies that the company is facing headwinds in commercialization, potentially due to market saturation, competition, or shifts in reimbursement policies within the cataract surgery space. As a non-dividend payer, the company does not distribute a dividend yield or maintains a payout ratio of 0.0%, meaning that any available cash flow is theoretically available for reinvestment into research and development or to reduce the existing debt load rather than being returned to shareholders. The overall growth and income profile is characterized by a contraction in revenue and a complete absence of current income distribution, which places the company in a phase of capital preservation and strategic restructuring rather than mature-stage expansion.